Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259255 | 0.84 | ADRB2 (0.55) | ADRB2ADRB1 | |
| SCHEMBL6258471 | 0.81 | ADRB2 (0.40) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6262196 | 0.81 | ADRB2 (0.40) | ADRB3ADRB2ADRB1 | |
| SCHEMBL6259212 | 0.81 | ADRB2 (0.57) | ADRB3ADRB2ADRB1 | |
| SCHEMBL9768276 | 0.80 | ADRA2A (0.44) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL28535211 | 0.80 | ADRA2A (0.62) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL6246174 | 0.71 | ADRB1 (0.40) | ADRB3ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL6261231 | 0.70 | MAPT (0.37) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4122825 | 0.68 | ADRB2 (0.50) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL10875410 | 0.68 | ADRB1 (0.50) | ADRB3ADRB2ADRB1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6951888-B2 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-04 | — | — | US | disclosed |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | CHRM1, CHRM2, ADRB1 | ADRB3 9/4885ADRA2A 11/4885ADRA2B 16/4885 |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | ADRA2C, ADRA1D, ADRB1 | ADRB3 7/4885ADRA2A 8/4885ADRA2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.